GLP-1 Drugs Show Promise for Heart Failure With Preserved Ejection Fraction, But Questions Remain | Research

The takeaway

GLP-1 receptor agonists improve symptoms in heart failure with preserved ejection fraction, with tirzepatide showing cardiovascular death reduction, but benefits in reduced ejection fraction remain uncertain.

Tirzepatide reduced CV death in obesity-HFpEF
While semaglutide improved symptoms without reducing mortality, tirzepatide significantly reduced cardiovascular death and worsening HF events in patients with obesity-related heart failure with preserved ejection fraction.

What the researchers found

Semaglutide improved symptoms, functional capacity, and weight loss in HFpEF patients but did not reduce HF hospitalizations or mortality. Tirzepatide showed broader benefits, significantly reducing cardiovascular death and worsening HF events in obesity-related HFpEF. For HFrEF, clinical evidence supporting major outcome improvements is lacking, and concerns exist about increased HF hospitalizations, fluid retention, and arrhythmic risk. The review identifies a clear distinction between HFpEF (positive signal) and HFrEF (uncertain/cautious) for GLP-1 RA use.

Why it matters

Heart failure affects over 60 million people worldwide, and HFpEF — which accounts for about half of all cases — has had very few effective treatments. GLP-1 peptide drugs represent one of the first medication classes to show meaningful benefits in HFpEF, particularly for the large subgroup of patients whose heart failure is driven by obesity and metabolic disease. This could fundamentally change how HFpEF is treated.

How the study worked

Narrative review synthesizing evidence from recent randomized controlled trials (including STEP-HFpEF, SELECT, and SUMMIT), mechanistic studies, and existing guidelines to evaluate GLP-1 RA efficacy and safety across the full spectrum of heart failure by ejection fraction.

What this study cannot tell us

The review is narrative rather than systematic. Key HFpEF trials excluded patients with very low ejection fractions, limiting extrapolation to HFrEF. The cardiovascular death reduction with tirzepatide was in obesity-related HFpEF specifically, and may not generalize to all HFpEF patients. Long-term safety in heart failure populations, particularly regarding fluid balance and arrhythmia risk, needs more data. The mechanisms behind GLP-1 RA benefits in HFpEF are not fully understood.

How to read the evidence

This is a narrative review synthesizing evidence from multiple large RCTs (high-quality primary evidence). The review itself does not present new data but provides a comprehensive clinical interpretation of the current trial landscape.

When this study was published

Published in 2025, this review incorporates the most recent trial results including SUMMIT (tirzepatide in HFpEF) and represents the current state of knowledge about GLP-1 drugs in heart failure.

The bigger picture

The expanding therapeutic applications of GLP-1 peptide drugs continue to surprise the medical community. From diabetes to obesity to now heart failure, these drugs are proving to have multi-organ benefits. The distinction between HFpEF (beneficial) and HFrEF (uncertain) highlights that GLP-1 drugs may work best in metabolic/obesity-driven conditions rather than in primarily structural heart disease, helping clinicians identify which patients are most likely to benefit.

Questions still open

Will ongoing trials confirm tirzepatide's cardiovascular death reduction in broader HFpEF populations?
Are the HFpEF benefits driven primarily by weight loss, or do GLP-1 drugs have direct cardiac effects?
Should GLP-1 drugs be avoided in HFrEF patients, or could certain subgroups still benefit?

Common questions

What is the difference between HFpEF and HFrEF?

In HFpEF (preserved ejection fraction), the heart pumps normally but is stiff and doesn't fill properly. It's often linked to obesity, diabetes, and aging. In HFrEF (reduced ejection fraction), the heart muscle is weakened and can't pump effectively. GLP-1 drugs appear to help HFpEF — likely because it's metabolically driven — but their role in HFrEF is uncertain.

Should heart failure patients start taking GLP-1 drugs?

It depends on the type of heart failure. For patients with HFpEF, especially those with obesity, the evidence supports discussing GLP-1 drugs with your cardiologist — particularly tirzepatide, which showed the strongest results. For patients with HFrEF, these drugs should be used cautiously if at all, due to concerns about fluid retention and other complications. Always consult your healthcare team.

Read the original research

Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure.

Biomolecules, 15(11)

View on PubMed ↗Publisher’s paper ↗

Citation

Crispino, Simone Pasquale; Nusca, Annunziata; Ferro, Aurora; Cricco, Riccardo; Ciancio, Martina; Segreti, Andrea; Cavallari, Ilaria; Sabatino, Mario; Potena, Luciano; Ussia, Gian Paolo; Grigioni, Francesco. (2025). Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure.. Biomolecules, 15(11). https://doi.org/10.3390/biom15111574